In the clinic: Ovid Therapeutics-OV101 and the engagement with the Angelman community
Ovid Therapeutics, a biopharmaceutical company, is actively engaged with the Angelman community and is committed to finding therapies for Angelman Syndrome. The company is focused on developing OV101, a drug that targets the GABA pathway and aims to restore balance in tonic inhibition, which is disrupted in Angelman Syndrome. Ovid has conducted clinical trials for OV101, including a Phase 1 PK trial in adolescents, and is currently enrolling patients for the STARS trial in adults and adolescents. The company plans to expand its trials to include younger age groups in the future. Ovid is also involved in various initiatives to support and engage with the Angelman community, including webinars, podcasts, and educational events.
In this talk, we will be discussing the work of Ovid Therapeutics and their engagement with the Angelman community. Ovid Therapeutics is a company dedicated to developing therapeutics for rare neurological disorders, with a particular focus on Angelman Syndrome. The CEO, Dr. Jeremy Levin, and the Chief Medical Officer, Dr. Amit Rakhit, will be presenting their work at the 2017 FAST Science Summit.
Ovid Therapeutics and their commitment to Angelman Syndrome
Ovid Therapeutics has been committed to Angelman Syndrome for the past three years. They have been a leader in the Angelman clinical trial agenda and have helped bring the entire agenda and disease forward. The company is based in New York and is focused on solving problems for patients with rare disorders of the brain.
The OV101 Program
The OV101 program is a key focus for Ovid Therapeutics. OV101 is a Delta Selective GABA Receptor Agonist, which aims to restore the balance of tonic inhibition in the brain. Tonic inhibition is imbalanced in many conditions that affect the central nervous system, including Angelman Syndrome. OV101 works by mimicking the effects of GABA, a neurotransmitter that is deficient in individuals with Angelman Syndrome.
The STARS Trial
The STARS trial is a clinical trial that is currently ongoing for OV101. The trial initially started with adults, but has now been expanded to include adolescents. The trial aims to determine the safety and efficacy of OV101 in individuals with Angelman Syndrome. The primary endpoint of the trial is the incidence of adverse events, and exploratory measures include motor function, behavior, sleep, and cognition.
Engaging with the Angelman Community
Ovid Therapeutics is dedicated to engaging with the Angelman community. They have collaborated with patient advocacy organizations such as FAST and the Angelman Syndrome Foundation. They have also hosted webinars and podcasts to provide information and answer questions from the community. Additionally, they have organized events and supported organizations such as Miracle Flights, which helps transport individuals with health care needs.
Ovid Therapeutics has plans to expand their clinical trial program to include younger age groups. They are currently working on fulfilling regulatory requirements for dosing and safety in younger children. They plan to announce specific age groups for future trials in the early part of 2018. Ovid Therapeutics is also actively involved in research and publications related to Angelman Syndrome.
Ovid Therapeutics is dedicated to developing therapeutics for rare neurological disorders, with a focus on Angelman Syndrome. They are actively engaged with the Angelman community and are committed to making a difference in the lives of individuals with the condition. Their OV101 program, including the ongoing STARS trial, shows promise in restoring the balance of tonic inhibition in the brain.
- Title: In the clinic: Ovid Therapeutics-OV101 and the engagement with the Angelman community
- Author(s): Amit Rakhit, Jeremy Levin
- Author(s)’ affiliation: Ovid Therapeutics
- Publication date: 2017-12-22
- Collection: 2017 FAST Science Summit